Mode
Text Size
Log in / Sign up

Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritisNew data shows infection risks for rheumatoid arthritis treatments

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that while b/tsDMARD monotherapy has similar infection risks to csDMARDs, combining them with adalimumab, infliximab, tofacitinib, or upadacitinib significantly increases serious infection risk.

This meta-analysis evaluated the safety profiles and risks associated with various biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA). The study included a large population of 55,749 patients to compare b/tsDMARD monotherapy and combination therapies against conventional synthetic DMARDs (csDMARDs). The primary outcome measured was the incidence of serious infections.

The analysis compared b/tsDMARD monotherapy directly against csDMARDs. For this specific comparison, the results indicated a similar risk of serious infection between b/tsDMARD monotherapy and cs104 DMARDs. Regarding other types of infections, the study found that b/tsDMARD monotherapy resulted in a similar risk for any infection compared to csDMARDs, with the exception of etanercept.

When evaluating combination therapies, the results showed significant increases in serious infection risks compared to csDMARDs alone. Specifically, the addition of adalimumab to csDMARDs resulted in an OR 1.51 (95% CI: 1.04-2.19). The combination of infliximab and csDMARDs showed a significantly increased risk with an OR 1.75 (95% CI: 1.09-2.81). Furthermore, the addition of tofacitinib to csDMARDs resulted in an OR 2.52 (95% CI: 1.26-5.03), and the combination of upadacitinib with csDMARDs showed an OR 2.31 (95% CI: 1.13-4.73).

Secondary outcomes included any infection, respiratory tract infections, gastroenteritis, and herpes zoster. Regarding herpes zoster, certain tsDMARDs were associated with an increased incidence compared to csDMARDs, except for filgotinib and peficitinib, which did not show this specific increase in the data provided. The study notes that these results are based on a network meta-analysis of randomized controlled trials.

Safety and tolerability findings specifically highlighted serious infections as the primary adverse event of concern. While specific rates for respiratory tract infections or gastroenteritis were noted as secondary outcomes, the primary focus remained on the significant risk elevation in combination therapies. The study notes that these results are based on pooled odds ratios from a network meta-analysis.

These findings contribute to the clinical landscape by providing a clear distinction between monotherapy and combination therapy risks. While b/tsDMARD monotherapy appears comparable to csDMARDs regarding serious infection risk, specific combinations involving adalimumab, infliximab, tofacitinib, or upadacitinib demonstrate significantly higher odds of serious infection. This suggests that the choice of therapy may depend heavily on whether a patient requires monotherapy or combination treatment.

Methodological limitations include the fact that this is a network meta-analysis where results for specific combinations are based on pooled odds ratios. Some data points, such as exact absolute numbers and specific p-values for all comparisons, were not reported in the summary. Clinical implications involve the development of a clinical reference pathway to inform drug selection optimization for RA patients receiving b/tsDMARDs.

Questions remain regarding the specific reasons why certain tsDMARDs like filgotinib and peficitinib did not show an increased incidence of herpes zoster compared to csDMARDs. Additionally, more data on the long-term tolerability of these combinations in diverse patient populations would further clarify the risk-benefit profile for individual clinical decision-making.

How this fits prior evidence

How this fits prior evidence: This meta-analysis provides a quantitative safety comparison between b/tsDMARD monotherapy and combination therapies. While previous reports noted that infliximab achieved clinical remission in a single case of AIFEC, this study highlights the increased risk of serious infection (OR 1.75) when infliximab is used in combination with csDMARDs for rheumatoid arthritis. It addresses a gap by quantifying the specific risks associated with various tsDMARD combinations compared to standard csDMARD therapy.

Living with rheumatoid arthritis means managing a condition that causes painful joint inflammation and stiffness. To manage this, many people use powerful medications called b/tsDMARDs. These drugs are often used alone or combined with older medications known as csDMARDs. Because these treatments affect the immune system, doctors must carefully weigh how well they control symptoms against the risk of causing infections.

To get a clearer picture of these risks, researchers looked at data from over 55,000 patients. They compared different ways of treating rheumatoid arthritis to see which combinations might lead to more serious health problems. This large pool of information helped them identify specific patterns in how certain drugs interact when used together.

The findings showed that using a b/tsDMARD on its own did not significantly increase the risk of serious infections compared to using only csDMARDs. However, the results changed when these medications were combined. Specifically, adding adalimumab, infliximab, tofacitinib, or upadacitinib to a standard csDMARD treatment was linked to a higher risk of serious infection than using the older medication alone. Additionally, some specific types of drugs were more likely to cause herpes zoster, which is a common viral infection.

It is important to remember that these results come from a network meta-analysis. This means the data comes from many different studies pooled together to find overall patterns. Because this is an analysis of existing data rather than a single new trial on one specific group of people, the results show associations rather than direct causes. The study also did not provide information on how many people stopped their medication due to side effects.

For patients right now, these findings do not mean that certain medications are unsafe. Instead, they provide a roadmap for doctors to make more informed choices. When choosing the best path forward, your medical team can use this data to pick the safest possible combination of drugs to keep your joints healthy while minimizing your risk of infection.

What this means for you:
Combining certain rheumatoid arthritis medications may increase infection risks compared to using them alone.

Study Details

Study typeSystematic review
Sample sizen = 55,749
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
OBJECTIVES: To evaluate infection risks in rheumatoid arthritis (RA) patients with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) as monotherapy or combined with conventional synthetic DMARDs (csDMARDs). METHODS: A comprehensive literature search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov from their inception to 31 October 2024 was conducted to identify randomized controlled trials (RCTs) assessing infection risks in RA patients receiving b/tsDMARDs. Primary outcome was serious infection incidence; secondary outcomes included any infection and specific events such as respiratory tract infections, gastroenteritis and herpes zoster. A frequentist network meta-analysis was performed to calculate odds ratios (ORs). RESULTS: A total of 127 RCTs involving 55,749 patients were included. b/tsDMARD monotherapy showed a similar risk of serious infections versus csDMARDs. Combining csDMARDs with adalimumab, infliximab, tofacitinib, or upadacitinib (though not with other b/tsDMARDs) was associated with a significantly increased risk of serious infections (OR 1.51, 95% CI: 1.04-2.19; OR 1.75, 95% CI: 1.09-2.81; OR 2.52, 95% CI: 1.26-5.03; OR 2.31, 95% CI: 1.13-4.73). For any infection, b/tsDMARD monotherapy posed a similar risk to csDMARDs, except for etanercept. Certain tsDMARDs were associated with an increased incidence of herpes zoster versus csDMARDs, except for filgotinib and peficitinib. CONCLUSION: Compared to csDMARDs, b/tsDMARD monotherapy showed no elevated serious infection risk, whereas specific combinations increased the risk of serious infections in RA patients. A clinical reference pathway was developed to inform drug selection optimization for RA patients receiving b/tsDMARDs.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.